Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma DOI

Yamei Huang,

Weiping Yu

British Journal of Hospital Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 21

Published: Sept. 30, 2024

The incidence and lethality of hepatocellular carcinoma (HCC) are increasing annually, traditional treatments have been proven to be ineffective for patients with advanced stages the disease. In recent years, immune checkpoint therapy has rapidly evolved, demonstrating promising results across a wide range cancers offering new hope cancer treatment. However, efficacy in HCC varies greatly among individuals, only small proportion responding positively. A major cause resistance poor is evasion, which often due insufficient infiltration cells. Understanding mechanisms underlying evasion crucial enhancing therapies. this review, we aim summarize observed during discuss future directions therapeutic approach. Our goal provide insights that could help overcome thereby improving therapies extending patient survival time.

Language: Английский

Cervical cancer: Novel treatment strategies offer renewed optimism DOI

Gangotri yadav,

Ganga Srinivasan,

Ashish Jain

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 254, P. 155136 - 155136

Published: Jan. 15, 2024

Language: Английский

Citations

18
REVIEWING ADVANCES IN UNDERSTANDING AND TARGETING THE MAPK SIGNALING PATHWAY IN HEPATOCELLULAR CARCINOMA PROGRESSION AND THERAPEUTICS DOI Creative Commons
Hassan Mushtaq, Yusra Zarlashat,

Alia Ambreen

et al.

Agrobiological Records, Journal Year: 2024, Volume and Issue: 15, P. 103 - 116

Published: Jan. 1, 2024

Hepatocellular carcinoma (HCC) is a severe and increasingly prevalent health issue affecting individuals globally. Recent research endeavors in the clinical domains have lately focused more on MAPK signaling pathway HCC. Activating mutations RAS RAF genes, which greatly activate malignancies, are rare HCC patients, yet over 50% of them activated pathway. This suggests that other factors may be responsible for activation important to carcinogenesis, it often altered human cancers. The drug resistance targeted therapy against RTKs arise from downstream components (RAS, RAF, MEK, ERK), resistant within RTKs, additional alternative pathways like PI3K YAP also develop resistance. Epigenetic processes chromatin remodeling crucial pharmacological tolerance regulation. review will focus latest developments our knowledge cellular molecular pathway, as well possible treatment approaches specifically target this relation study investigates efficacy molecular-targeted treatments, including tyrosine kinase inhibitors immunological checkpoint highlights use combination

Language: Английский

Citations

2
Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma DOI

Caiyan Liu,

Xiaowei Lin,

Manru Huang

et al.

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 334, P. 118540 - 118540

Published: July 9, 2024

Language: Английский

Citations

2
Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review DOI Open Access

Gaocheng Wang,

Jingjing Wang, Shuilin Dong

et al.

Experimental and Therapeutic Medicine, Journal Year: 2024, Volume and Issue: 27(5)

Published: March 12, 2024

Treatment with immune checkpoint inhibitors (ICIs) is steadily becoming the standard of care for hepatocellular carcinoma (HCC), an increasing number immune‑related adverse events (irAEs). However, only a small reports on occurrence diabetes mellitus (DM) in patients HCC treated ICIs have been published. In present study, clinical manifestations, laboratory findings, treatment and prognosis three advanced were reported, who suffered DM when receiving ICIs. Furthermore, relevant literature was reviewed order to summarize possible mechanisms, diagnosis, rechallenge recommended management options, as well suggestions. ICI‑induced rare but irAEs are potentially fatal, diabetic ketoacidosis (DKA) often first manifestation. The incidence 0.86% among those cases, DKA 59%. combination two markedly increases risk. human leukocyte antigen genotype, islet autoantibodies autoreactive T cell‑mediated β‑cell destruction may be linked DM. Patient education clinicians' awareness ICI‑related good options. Adequate judgment, close monitoring early detection also needed decide whether continue immunotherapy or it, so achieve maximum benefit treatment.

Language: Английский

Citations

1
Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma DOI

Yamei Huang,

Weiping Yu

British Journal of Hospital Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 21

Published: Sept. 30, 2024

The incidence and lethality of hepatocellular carcinoma (HCC) are increasing annually, traditional treatments have been proven to be ineffective for patients with advanced stages the disease. In recent years, immune checkpoint therapy has rapidly evolved, demonstrating promising results across a wide range cancers offering new hope cancer treatment. However, efficacy in HCC varies greatly among individuals, only small proportion responding positively. A major cause resistance poor is evasion, which often due insufficient infiltration cells. Understanding mechanisms underlying evasion crucial enhancing therapies. this review, we aim summarize observed during discuss future directions therapeutic approach. Our goal provide insights that could help overcome thereby improving therapies extending patient survival time.

Language: Английский

Citations

0